(PHRM) - exceeded earnings estimates in eight out of the past nine quarters, with each of the positive surprises exceeding 20%

Pharmion Corporation (PHRM) has exceeded earnings estimates in eight out of the past nine quarters, with each of the positive surprises exceeding 20%. Three analysts have raised their numbers for this year. The latest earnings surprise was 111%. The company is losing money, but this year's loss estimate has been reduced from $1.12 per share to 97 cents per share over the past 90 days. PHRM has a long-term growth rate of 29%. Full Analysis Pharmion Corporation is a global pharmaceutical company focused on acquiring, developing, and commercializing products for treating hematology and oncology patients. It has established a regulatory, development, and sales & marketing organization covering the U.S., Europe, and Australia. The company has also developed a distributor network to serve the hematology and oncology markets in two-dozen additional countries throughout the Middle East and Asia. Pharmion has acquired marketing and distribution rights for two drugs - Innohep and Refludan. Innohep belongs to the anticoagulant family of drugs, which are generally prescribed to prevent or treat blood clots. Refludan is an antithrombin agent for the treatment of heparin-induced thrombocytopenia type II. The FDA approval and launch of Vidaza in July 2004 helped Pharmion deliver revenue growth up nearly 70% in 2005 to $221.3 million. The drug was also the driving force behind the company's first year of positive earnings. Vidaza (Azacitidine) is a once a day subcutaneous injection administered for a period of at least 4 weeks. It is approved for the treatment of myelodysplastic syndrome (MDS), a market of about 30,000-40,000 patients in the U.S. At the ASCO annual meeting in June 2006, Pharmion Corporation presented data from seven studies investigating the use of Vidaza in hematologic and solid tumor cancers. The seven studies investigate a variety of uses for Vidaza -- including alternative dosing schedules, and combination use with approved and/or investigational therapies, such as thalidomide, carboplatin and the histone deacetylase inhibitor valproic acid (VPA). The company has exceeded earnings estimates in eight out of the past nine quarters, with each of the positive surprises exceeding 20%. Three analysts have raised their numbers for this year. The latest earnings surprise was 111%. The company is losing money, but this year's loss estimate has been reduced from $1.12 per share to 97 cents per share over the past 90 days. PHRM has a long-term growth rate of 29%. Note: The Zacks Rank is a very sensitive indicator that can change frequently for an individual stock. This important indicator is updated daily on Zacks.com and is available to Zacks Premium subscribers. As such, it is prudent to check the site for the latest Zacks Rank on the stocks highlighted in this section. Simply click the link for the stock or enter the symbol in the ticker entry box in the upper left hand corner of the web site. Content Courtesy: Zacks Investment Research #1 Ranked Stocks Highlight Archive To truly take advantage of the Zacks Rank, you need to first understand how it works. That is why we created the free special report: Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions. Blog Home